Risk factors
Spyre Therapeutics (SYRE) risk factors
Item 1A of every Spyre Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks11 new9 dropped24 reworded
Capital needs and an accumulated deficit of $1.1 billion remain central risks as Spyre funds development of its programs.
Filed Feb 19, 2026 - FY2024 10-K risk factors62 risks
This company has no prior year filing and is dominated by risks of capital requirements, clinical trials, and intellectual property protection.
Filed Feb 27, 2025